About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company’s progress in its Phase 2 study targeting basal cell carcinoma — the most common form of skin cancer. Bokhari shared that over 75% of the 90 patients in the proof-of-concept trial have been randomized, with full enrollment expected by the end of the year. The study is investigating a novel, non-invasive treatment option. Bokhari confirmed that Medicus Pharma has requested a Type C meeting with the US Food and Drug Administ ...

Core Insights - Medicus Pharma Ltd. is advancing its clinical development program for a novel microneedle array (D-MNA) aimed at treating basal cell carcinoma (BCC) of the skin, with significant progress in its Phase 2 study [1][3][8] - The company has received FDA acceptance for a Type C meeting to discuss the D-MNA product development and seek fast-track approval for its clinical program [1][2] - Financial highlights for Q2 2025 indicate a net loss of $6.2 million, an increase in cash reserves to $9.7 million, and total operating expenses of $6.0 million, reflecting the company's investment in clinical development [12][13][15] Clinical Development - The SKNJCT-003 Phase 2 study has randomized over 75% of the 90 participants, focusing on the efficacy of D-MNA compared to a placebo [3][8] - The study is designed as a randomized, double-blind, placebo-controlled trial, evaluating two dose levels of D-MNA (100μg and 200μg) against a placebo [4][5] - An interim analysis in March 2025 showed over 60% clinical clearance among participants, with the study currently ongoing at nine clinical sites in the U.S. [8] Financial Performance - The company reported $11.5 million in net proceeds from financing and warrant exercises, enhancing its balance sheet [13] - Cash and cash equivalents increased from $4.0 million at the end of Q1 2025 to $9.7 million at the end of Q2 2025 [13] - Operating expenses rose to $6.0 million in Q2 2025 from $3.6 million in the same period in 2024, with R&D expenses slightly increasing to $1.4 million [13] Strategic Initiatives - Medicus Pharma is pursuing strategic transactions, including the acquisition of Antev Ltd., a UK-based biotech company focused on a GnRH antagonist for prostate cancer [10][18] - A non-binding memorandum of understanding has been established with Helix Nanotechnologies Inc. to explore the development of mRNA vaccines [11] - The company is also conducting a clinical study (SKNJCT-004) in the UAE, aiming to randomize 36 patients across four sites [9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission file number: 001-42408 MEDICUS PHARMA LTD. (Exact Name of Registrant as Specified in Its Charter) Ontario, Canada 98-1778211 (State or ot ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Core Viewpoint - Medicus Pharma Ltd. and Helix Nanotechnologies Inc. have entered into a non-binding memorandum of understanding (MoU) to collaborate on the development of thermostable infectious disease vaccines by integrating their proprietary technologies [1][2]. Group 1: Collaboration Details - The MoU aims to combine HelixNano's mRNA vaccine platform with Medicus' microneedle array (MNA) delivery system for the co-development and commercialization of thermostable mRNA-based vaccines [1][2]. - Both companies are engaged in good faith negotiations to form a joint venture for this purpose [2]. - The collaboration includes a project to develop clinical-grade mRNA vaccine-loaded MNAs for a Phase 1 clinical bridging study comparing intramuscular injection and intradermal MNA delivery of HelixNano's vaccine candidate HN-0001 [3]. Group 2: Technological Innovations - The combination of HelixNano's mRNA platform and Medicus' MNA technology aims to create needle-free, thermostable vaccines that could eliminate cold-chain logistics, reduce distribution costs, and improve patient access [4]. - The project is expected to position the companies at the forefront of opportunities to prevent infectious diseases rather than just treating them [4]. Group 3: Research and Development Activities - Medicus and HelixNano will enter into a Sponsored Research Agreement with the University of Pittsburgh to conduct parts of the project under the direction of Dr. Lou Falo [6]. - HelixNano will supply the clinical drug product HN-0001 for the project, while the University will optimize the incorporation of this product into microneedle arrays [7][8]. Group 4: Non-Binding Nature of the MoU - The MoU is non-binding and does not obligate either party to proceed with the joint venture or any further development until definitive agreements are executed [9].

Core Points - Medicus Pharma Ltd. held its annual and special meeting of shareholders on July 22, 2025, where all resolutions were passed [1] - The company elected all eight nominees for the board of directors, including Congresswoman Cathy McMorris Rodgers and Ajay Raju [2][3] - The shareholders expressed pride in electing a diverse and experienced leadership team in drug development and governance [2] Board Members - Congresswoman Cathy McMorris Rodgers has a distinguished record in public service, serving as a U.S. Representative for Washington's 5th Congressional District from 2004 to 2025 [4][5] - Ajay Raju is an attorney and venture capitalist with extensive experience in structured finance, real estate, and life sciences [8] - Dr. Raza Bokhari serves as Executive Chairman and CEO, with a background in life sciences and healthcare services [9][10] - Other continuing board members include Dr. Larry Kaiser, Robert J. Ciaruffoli, William L. Ashton, Barry Fishman, and Dr. Sara R. May, each bringing significant experience in their respective fields [13][14][15][16][17] Shareholder Approvals - Shareholders approved the appointment of KPMG LLP as auditors and authorized the board to fix the auditors' remuneration [18] - An amendment to the company's by-laws was approved to increase the quorum requirement for shareholder meetings [18] - Approval was granted for the issuance of common shares under the Standby Equity Purchase Agreement, which may exceed 20% of the outstanding shares [18] - An amendment to increase the voting threshold required to remove the Chairman of the Board to 75% was also approved [18] Company Overview - Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating clinical development programs for novel therapeutics [20] - The company is engaged in multiple countries across three continents [20] - SkinJect Inc., a subsidiary of Medicus, is developing a non-invasive treatment for basal cell skin cancer using a dissolvable microneedle patch [21] - The company announced a definitive agreement to acquire Antev, a UK-based biotech company, which is subject to certain closing conditions [22]

Executive Chairman & CEO of the Company to Participate in a Fireside Chat Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025 Philadelphia, Pennsylvania--(Newsfile Corp. - July 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the scheduling of the Fireside chat of Dr. Raza Bokhari, Executive Chairman and CEO, at the BTIG Virtual Biotech Conference 2025. Fireside Chat Event Details Date: Wednesday, July 30, 2025 Time: 9:20 a.m. ET The Fires ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive is a forward-looking company that adopts technology enthusiastically, utilizing decades of expertise and experience [4] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - Medicus Pharma Ltd. has submitted a request for a Type C meeting with the FDA to discuss the fast-tracking of its clinical development program for treating Basal Cell Carcinoma (BCC) using Dissolvable Doxorubicin-containing Microneedle Arrays (D-MNA) [1][2] Group 1: Clinical Development Program - The Type C meeting aims to align on the clinical pathway and seek FDA feedback on the D-MNA product development [2] - The clinical study SKNJCT-003 is a randomized, double-blind, placebo-controlled trial enrolling up to 60 subjects with BCC, evaluating two dose levels of D-MNA against a placebo [2][5] - The high-dose of 200μg D-MNA is the maximum dose used in the previous Phase 1 safety study, which was completed in March 2021 [3][5] Group 2: Study Design and Objectives - The company seeks FDA agreement on several key topics, including the appropriateness of selected doses, primary endpoints, patient population definitions, study design, and safety assessments for future studies [4] - The Phase 1 study (SKNJCT-001) met its primary objective of safety and tolerability, with no serious adverse events reported and six participants achieving complete responses [5][10] Group 3: Ongoing and Future Studies - The Phase 2 clinical study (SKNJCT-003) is currently underway at nine clinical sites in the U.S., with an interim analysis showing over 60% clinical clearance [6] - The number of participants in SKNJCT-003 has been increased to 90, and the company is expanding clinical trial sites to Europe [6] - A separate clinical study (SKNJCT-004) is being conducted in the UAE, aiming to randomize 36 patients across four sites [7] Group 4: Strategic Acquisitions - In June 2025, the company announced a definitive agreement to acquire Antev Limited, a UK-based biotech company developing Teverelix for advanced prostate cancer [8][11]